Reuters logo
BRIEF-Esperite unit develops extracellular vesicles biologic drug
May 5, 2017 / 8:41 AM / 5 months ago

BRIEF-Esperite unit develops extracellular vesicles biologic drug

May 5 (Reuters) - Esperite NV:

* Esperite’s biotech subsidiary cell factory develops extracellular vesicles (EVS) biologic drug (CF-MEV-117) for treatment of drug-resistant epilepsy in children Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below